• Policy
• Green light to Sprycel's reimb with indication expansion
• by Lee, Tak-Sun May 20, 2022 06:11am

• Opinion
• The Minister should be appointed to lead policy continuity
• by Lee, Hye-Kyung May 20, 2022 06:11am

• Policy
• HIRA plans to improve the overall management system
• by Lee, Tak-Sun May 20, 2022 06:11am

• Company
• The standard of Xospata is very disappointing
• by Eo, Yun-Ho May 19, 2022 05:51am

• Company
• Samsung Bioepis makes ₩199.1 bil in Q1
• by Chon, Seung-Hyun May 19, 2022 05:51am

• Company
• Samsung Bioepis’s Lucentis biosimilar approved in Korea
• by Lee, Seok-Jun May 18, 2022 10:42pm

• Policy
• 34 new global drugs, including Beleodaq, are urgently needed
• by Lee, Tak-Sun May 18, 2022 05:52am

• Opinion
• [Reporter’s View] New govnt signals expanded PE exemptions
• by Eo, Yun-Ho May 18, 2022 05:52am

• Policy
• MFDS promotes RWD analysis of COVID-19 vaccines & txs
• by Lee, Hye-Kyung May 18, 2022 05:51am

• Company
• Shionogi applies to trademark its COVID-19 treatment
• by Kim, Jin-Gu May 17, 2022 06:02am